Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2858 13/10/2025 fruquintinib (Fruzaqla) Resubmission

For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and, if RAS wildtype and medically appropriate, an anti-EGFR therapy
SMC2812 09/06/2025 pegylated liposomal irinotecan (Onivyde) Non submission

In combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas
SMC2654 12/08/2024 trifluridine tipiracil (Lonsurf) Full

In combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.
1217/17 13/03/2017 liposomal irinotecan (Onivyde) Full Treatment of metastatic adenocarcinoma of the pancreas, in combination with fluorouracil (5-FU) and leucovorin (folinic acid), in adult patients who have progressed following gemcitabine based therapy.
1221/17 13/02/2017 trifluridine/tipiracil (Lonsurf) Full for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents.
1156/16 09/05/2016 ramucirumab (Cyramza) Non submission In combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.
1012/14 12/01/2015 cetuximab (Erbitux) Full Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer: in combination with irinotecan-based chemotherapy; in first-line in combination with FOLFOX; as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
769/12 13/02/2012 panitumumab (Vectibix) Non submission Metastatic colorectal cancer (mCRC)
486/08 09/06/2008 panitumumab 20mg/ml concentrate for solution for infusion (Vectibix) Non submission as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma
221/05 05/06/2006 bevacizumab (Avastin) Resubmission Metastatic colorectal cancer
155/05 10/10/2005 cetuximab (Erbitux) IRP In combination with irinotecan for the treatment of patients with epidermal growth factor receptor expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy

No medicines have been found.